Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Warren, MI
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Warren, MI
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
mi
from
Bethpage, NY
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
mi
from
Bethpage, NY
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mineola, NY
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mineola, NY
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wilmington, NC
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Worth, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
DaVita Clinical Research
mi
from
Minneapolis, MN
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
NOCR-Knoxville
mi
from
Knoxville, TN
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
NOCR-Knoxville
mi
from
Knoxville, TN
Click here to add this to my saved trials
Pilot Study of Health Information Technology for Chronic Kidney Disease Management
Pilot Study of Health Information Technology for Chronic Kidney Disease Management
Status: Enrolling
Updated:  12/31/1969
North Shore Physicians Group
mi
from
Danvers, MA
Pilot Study of Health Information Technology for Chronic Kidney Disease Management
Pilot Study of Health Information Technology for Chronic Kidney Disease Management
Status: Enrolling
Updated: 12/31/1969
North Shore Physicians Group
mi
from
Danvers, MA
Click here to add this to my saved trials
Effect of Venglustat in Patients With Renal Impairment
A Phase I, Single-Center, Open-label, Single Dose Pharmacokinetic and Tolerability Study of GZ402671 in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Effect of Venglustat in Patients With Renal Impairment
A Phase I, Single-Center, Open-label, Single Dose Pharmacokinetic and Tolerability Study of GZ402671 in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
Status: Enrolling
Updated:  12/31/1969
Orlando Cliniical Research Associates
mi
from
Orlando, FL
VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
Status: Enrolling
Updated: 12/31/1969
Orlando Cliniical Research Associates
mi
from
Orlando, FL
Click here to add this to my saved trials
VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
Status: Enrolling
Updated:  12/31/1969
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
Status: Enrolling
Updated: 12/31/1969
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Pilot Analysis of the Association Between Anesthesia Induction Dosing and AKI in the Elderly Population
A Pilot Analysis of the Association Between Anesthesia Induction Dosing and Acute Kidney Injury (AKI) in the Elderly Population
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Health System
mi
from
New Haven, CT
A Pilot Analysis of the Association Between Anesthesia Induction Dosing and AKI in the Elderly Population
A Pilot Analysis of the Association Between Anesthesia Induction Dosing and Acute Kidney Injury (AKI) in the Elderly Population
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Health System
mi
from
New Haven, CT
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
Harbor UCLA Medical Center
mi
from
Torrance, CA
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
Atlanta VA Medical Center, Emory University School of Medicine
mi
from
Atlanta, GA
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical Center, Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
William Beaumont Hospital
mi
from
Royal Oak, MI
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
North Mississippi Medical Center
mi
from
Tupelo, MS
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
North Mississippi Medical Center
mi
from
Tupelo, MS
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
WakeMed Heart and Vascular
mi
from
Raleigh, NC
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
WakeMed Heart and Vascular
mi
from
Raleigh, NC
Click here to add this to my saved trials
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated:  12/31/1969
Christ Hospital, Heart and Vascular Center, Lindner Research Center
mi
from
Cincinnati, OH
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Minimizing Radiographic Contrast Administration During Coronary Angiography Using a Novel Contrast Reduction System: A Multicenter Observational Study of the DyeVert™ Plus Contrast Reduction System
Status: Enrolling
Updated: 12/31/1969
Christ Hospital, Heart and Vascular Center, Lindner Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients
Prospective, Randomized Controlled Trial Using CPV Vignettes to Assess the Clinical Utility of Natera Dd-cfDNA Test to Detect Allograft in Post-Transplant Patients
Status: Enrolling
Updated:  12/31/1969
QURE Healthcare
mi
from
San Francisco, CA
Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients
Prospective, Randomized Controlled Trial Using CPV Vignettes to Assess the Clinical Utility of Natera Dd-cfDNA Test to Detect Allograft in Post-Transplant Patients
Status: Enrolling
Updated: 12/31/1969
QURE Healthcare
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Nephrology Consultants
mi
from
Huntsville, AL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Nephrology Consultants
mi
from
Huntsville, AL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
The Medical Research Group, Inc.
mi
from
Fresno, CA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
The Medical Research Group, Inc.
mi
from
Fresno, CA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
DaVita Clinical Trials, LLC
mi
from
Long Beach, CA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
DaVita Clinical Trials, LLC
mi
from
Long Beach, CA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Southland Renal Medical Group
mi
from
Long Beach, CA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Southland Renal Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Valley Renal Medical Group Research
mi
from
Northridge, CA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Valley Renal Medical Group Research
mi
from
Northridge, CA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Summit Nephrology Medical Group, Inc.
mi
from
Roseville, CA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Summit Nephrology Medical Group, Inc.
mi
from
Roseville, CA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Satellite Healthcare, Inc.
mi
from
San Jose, CA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Satellite Healthcare, Inc.
mi
from
San Jose, CA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Washington Nephrology Associates
mi
from
Washington,
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Washington Nephrology Associates
mi
from
Washington,
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
South Florida Nephrology Group PA, Research Division
mi
from
Coral Springs, FL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
South Florida Nephrology Group PA, Research Division
mi
from
Coral Springs, FL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
LG. Diagnostic, Inc. & Cosmetic Center
mi
from
Miami, FL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
LG. Diagnostic, Inc. & Cosmetic Center
mi
from
Miami, FL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Nuren Medical & Research Center
mi
from
Miami, FL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Nuren Medical & Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Medical Professional Clinical Research Center
mi
from
Miami, FL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Medical Professional Clinical Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Boise Kidney and Hypertension Institute
mi
from
Meridian, ID
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Boise Kidney and Hypertension Institute
mi
from
Meridian, ID
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
NANI Research
mi
from
Crystal Lake, IL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
NANI Research
mi
from
Crystal Lake, IL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
NANI Research
mi
from
River Forest, IL
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
NANI Research
mi
from
River Forest, IL
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
NANI Research
mi
from
Fort Wayne, IN
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
NANI Research
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Northwest Louisiana Nephrology
mi
from
Shreveport, LA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Northwest Louisiana Nephrology
mi
from
Shreveport, LA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Anne Arundel Medical Center
mi
from
Annapolis, MD
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Anne Arundel Medical Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Washington Nephrology Associates
mi
from
Takoma Park, MD
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Washington Nephrology Associates
mi
from
Takoma Park, MD
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
South Shore Nephrology, P.C.
mi
from
Plymouth, MA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
South Shore Nephrology, P.C.
mi
from
Plymouth, MA
Click here to add this to my saved trials
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Renal and Transplant Associates of New England, PC
mi
from
Springfield, MA
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Renal and Transplant Associates of New England, PC
mi
from
Springfield, MA
Click here to add this to my saved trials